Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.52 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 5/20 | 0.50 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | NAPRT | Q6XQN6 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | KDM6B | O15054 | 1/20 | 0.42 |
| ▸ | TET3 | O43151 | 1/20 | 0.42 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL23496608 | 0.94 | KDM4E (0.48) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL1427584 | 0.87 | KDM4E (0.42) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL3174349 | 0.87 | NNMT (0.57) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL31058098 | 0.87 | KCNJ1 (0.46) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL2177672 | 0.84 | GABRP (0.43) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL10963802 | 0.84 | KDM4E (0.41) | KDM4ETSHRALOX15ACMSDTDP1 | |
| Water SCHEMBL2130375 | 0.84 | KDM4E (0.41) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL380569 | 0.84 | JUN (0.45) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL3889503 | 0.84 | KDM4E (0.42) | KDM4ETSHRALOX15ACMSDTDP1 | |
| SCHEMBL15921063 | 0.84 | KDM4E (0.48) | KDM4ETSHRALOX15ACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119836101-A | Perovskite solar cell based on diamine molten salt surface modification and preparation method thereof | 东方电气长三角(杭州)创新研究院有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-117797875-A | Preparation method of zirconium-based metal organic framework-based photocatalytic material and light stability research method thereof | 中国科学技术大学 | 2024-04-02 | — | — | CN | claimed |
| US-8968711-B2 | Cosmetic or dermatological composition comprising a polymer bearing junction groups, and cosmetic treatment process | L'OREAL (FR) | 2015-03-03 | — | — | US | claimed |
| US-8653048-B2 | Prodrugs based on gemcitabine structure and synthetic methods and applications thereof | SANLUGEN PHARMATECH LTD. (CN) | 2014-02-18 | — | — | US | claimed |
| CN-102428093-A | Prodrugs based on gemcitabine structure as well as synthetic method and application thereof | SANLUGEN PHARMATECH LTD | 2012-04-25 | — | — | CN | claimed |
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | SANLUGEN PHARMATECH LTD. (CN) | 2012-04-12 | — | — | US | claimed |
| EP-2423215-A1 | PRODRUGS BASED ON GEMCITABINE STRUCTURE AS WELL AS SYNTHETIC METHOD AND APPLICATION THEREOF | Sanlugen Pharmatech Ltd. (CN) | 2012-02-29 | — | — | EP | claimed |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | L'OREAL (FR) | 2010-10-28 | — | — | US | claimed |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | L'OREAL (FR) | 2010-09-23 | — | — | US | claimed |
| EP-1529247-A1 | USE OF SALTS OF LAYERED DOUBLE HYDROXIDES | Clariant GmbH (DE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004019138-A1 | USE OF SALTS OF LAYERED DOUBLE HYDROXIDES | CLARIANT GMBH (DE) | 2004-03-04 | — | — | WO | claimed |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2026-03-19 | — | — | US | disclosed |
| US-12516044-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250154143-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | UCL BUSINESS LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| CN-119836101-A | Perovskite solar cell based on diamine molten salt surface modification and preparation method thereof | 东方电气长三角(杭州)创新研究院有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2001007415-A1 | METHOD OF PRODUCING PYRIDAZINE-3,6-DICARBOXYLIC ACID ESTERS | LONZA AG (CH) | 2001-02-01 | — | — | WO | disclosed |
| EP-0603557-B1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM CO (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5461126-A | Process of polymerizing olefins using organonickel catalyst compositions | PHILLIPS PETROLEUM COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| US-5332708-A | Ethylene polymerization catalyst, organonickel compound and a heterocyclic nitrogen compound | PHILLIPS PETROLEUM COMPANY (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0603557-A1 | Catalyst compositions and catalytic processes | PHILLIPS PETROLEUM COMPANY (US) | 1994-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088908-A1 | Prodrugs Based on Gemcitabine Structure and Synthetic Methods and Applications Thereof | TYMP, DCTD, GLS2 | KDM4E 2472/4885TSHR 4200/4885ALOX15 2359/4885 |
| US-20100239509-A1 | COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS | CUTA, SUCLG1, KRT18 | KDM4E 2504/4885TSHR 4385/4885ALOX15 914/4885 |
| US-20260078113-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | MSR1, NR3C1, CCR1 | KDM4E 4270/4885TSHR 113/4885ALOX15 748/4885 |
| US-20100272660-A1 | COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT | ACMSD, CUTA, PCCA | KDM4E 1109/4885TSHR 2885/4885ALOX15 383/4885 |
| US-20250154143-A1 | PRODRUGS FOR USE IN THE TREATMENT OF TISSUE DAMAGE | CYP2B6, CBR3, CYP2A6 | KDM4E 4634/4885TSHR 86/4885ALOX15 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.